Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BDX · NYSE · Health Care Equipment
Becton Dickinson (BDX) · oqro.io/stocks/BDX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Becton Dickinson was filed in the last 90 days. The latest on record was on Aug 11, 2025.
Since 2006, Becton Dickinson insiders reported 10 open-market purchases and 490 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2025.
In the last 90 days, 2 insiders of Becton Dickinson (BDX) reported 4 open-market sales worth $689K in total on SEC Form 4. The largest seller by value was Thomas E Jr Polen, with $629K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 3 trades in Becton Dickinson (BDX) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Sen. Alan Armstrong, Rep. Thomas H. Kean Jr. (NJ07), Rep. Kevin Hern (OK01).
Becton Dickinson's next results are expected on Feb 8, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$216.08+0.66 (+0.31%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
+12.3% (+$23.75) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $192.33 on Nov 18, 2025 to $216.08 on Nov 18, 2026 (+12.3%). Disclosed in this range: 16 insider trades, 6 pre-arranged insider sales, 3 Congress trades, and 93 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Equipment company based in Franklin Lakes, New Jersey.
Last 12 months
+12.3%
Market value
$58.9B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 8.11M shares sold short (3.0% of shares outstanding), −9.0% vs the previous count, 5.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$4.98B
+5.4% vs the same quarter a year earlier
Free cash flow, last 12 months
$633M
This quarter $633M, a year earlier $925M
Net debt
$16.1B
Debt $16.8B, cash $708M, at Jun 30, 2026
Net income, last 12 months
$941M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Revenue, fiscal 2025
$21.8B
+8.2% vs the year before
Net income, fiscal 2025
$1.68B
As reported in the annual filing
Shares outstanding
272M
As of Jun 30, 2026
In fiscal 2025 the company spent $1B buying back its own shares and $1.2B on dividends. Cash actually paid, from its cash-flow statement.
Next ex-dividend date Dec 10, 2026: $1.06 a share (quarterly), payable Dec 31, 2026. Calendar
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Insider selling
Traded Nov 10 · filed the same day
A Becton Dickinson officer told the SEC about a plan to sell $397K of Becton Dickinson shares around Nov 10, 2026. The shares were not acquired as compensation.
Thomas Polen (Officer) plans to sell ~$626K of Becton Dickinson
Planned, from payPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Becton Dickinson over the 12 months to Nov 19, 2026: 93 FDA records (4th most among listed companies) and 1 WARN notice.
Top officer leaving
“Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire.”
3 insiders sold ~$754K in the 60 days before
8-K on sec.govTop officer leaving
“Byrd, Executive Vice President and President of the Interventional segment of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire.”
2 insiders sold ~$199K in the 60 days before
8-K on sec.govTop officer leaving
“DelOrefice informed Becton, Dickinson and Company (the “Company” or “BD”) of his intention to resign from his position as the Company’s Executive Vice President and Chief Financial Officer effective December 5, 2025 to pursue a new professional opportunity.”
2 insiders sold ~$194K in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Written by software from the filings listed below · Oct 28, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up freeInsiders of Becton Dickinson reported 10 open-market purchases and 490 sales since 2006; purchases in 5 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $3.22M19×19 trades |
| 2025 | $1.36M2×2 trades | $2.41M20×20 trades |
| 2024 | — | $4.42M14×14 trades |
| 2023 | — | $2.71M7×7 trades |
| 2022 | — | $13.5M17×17 trades |
| 2021 | — | $4.41M15×15 trades |
| 2020 | — | $42.3M21×21 trades |
| 2019 | $7.4K1×1 trade | $38.1M36×36 trades |
| 2018 | $188K3×3 trades | $91M32×32 trades |
| 2017 | — | $28.5M19×19 trades |
| 2016 | — | $30.6M24×24 trades |
| 2015 | — | $24.7M34×34 trades |
| 2014 | — | $3.59M6×6 trades |
| 2013 | — | $18.9M28×28 trades |
| 2012 | — | $9.06M14×14 trades |
| 2011 | — | $20.7M14×14 trades |
| 2010 | — | $69.3M57×57 trades |
| 2009 | $1.33M3×3 trades | $7.35M10×10 trades |
| 2008 | $90K1×1 trade | $56.3M33×33 trades |
| 2007 | — | $69.6M39×39 trades |
| 2006 | — | $46.4M31×31 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
People read Becton Dickinson's Wikipedia article about 150 times a day over the last week, close to the 180 on a usual day of the three months before.
May 14, 2026Busiest day: 370 views on Jun 8, 2026Nov 18, 2026
Views of the article BD (company), by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 8, 2027
Purchases after results
Not enough history
From Becton Dickinson's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Becton Dickinson's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Vanguard Capital Management
13G · passive · Crossed 5% · 21.4M shares · filed Apr 29, 2026
STATE STREET CORPORATION
13G · passive · Crossed 5% · 15M shares · filed Aug 7, 2026
Vanguard Portfolio Management
13G · passive · Crossed 5% · 15.4M shares · filed Apr 29, 2026
First Eagle Investment Management, LLC
13G · passive · Crossed 5% · 14.1M shares · filed Aug 6, 2026
Recent moves
STATE STREET CORPORATION went above 5%, with 5.4% · Schedule 13G, 2026
First Eagle Investment Management, LLC went above 5%, with 5.1% · Schedule 13G, 2026
T. Rowe Price Investment Management, Inc. fell below 5% (3.4%) · Schedule 13G, 2026
Vanguard Capital Management went above 5%, with 7.51% · Schedule 13G, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
3 notices filed with state agencies, covering 151 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
Vanguard Portfolio Management went above 5%, with 5.4% · Schedule 13G, 2026
51 certified in FY2026 Q3, vs 89 a year earlier. 51 positions in total, median offered wage $118K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Short sale volume: 41.6% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 50.6%. FINRA daily files, to Nov 18, 2026.
Fails to deliver: 5,828 shares (about $1.05M) were not delivered on time for settlement on Oct 7, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 43.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (30.7% on ATS, 12.5% with other brokers), close to its 26-week average of 45.1%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: UBS ATS (13.3%), SIGMA X2 (11.9%), INTELLIGENT CROSS LLC (11.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Attention
Things to keep in mind
Records
19 approvals or clearances and 75 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Latest annual report filed Nov 25, 2025, compared with the one filed Nov 27, 2024. Read the filing
Information with respect to certain legal proceedings is included in Note 6 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, and is incorporated herein by reference.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Nov 25, 2025. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Against the S&P 500 over the year
Since Nov 17, 2025, BDX is up 13.1% and the index fund is up 9.7%: 3 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much BDX moves
Beta 0.3 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).